2 news items
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
LRMR
20 May 24
planned product candidates, Larimar's planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
LRMR
9 May 24
of 2023. Research and development expenses for the first quarter of 2024 were $12.9 million, compared to $4.6 million
- Prev
- 1
- Next